In a significant stride for urological health, Rigicon Inc. proudly announces groundbreaking enhancements to its ContiReflex® artificial urinary sphincter and Testi10 testicular prosthesis. These state-of-the-art developments, recently showcased at the American Urological Association meeting and featured in the International Journal of Impotence Research, mark a pioneering leap in medical technology. With the latest ContiReflex® model, Rigicon introduces a novel dual-bladder system, designed to offer unmatched control and comfort for patients suffering from male stress incontinence. Meanwhile, the Testi10 testicular prosthesis sets a new standard in prosthetic reliability and patient safety, achieving a remarkable 99.8% survival rate over 54 months. Rigicon's commitment to innovation and patient care continues to redefine industry standards and improve the quality of life for patients globally.
RONKONKOMA, N.Y., May 12, 2024 /PRNewswire-PRWeb/ -- Rigicon Inc., a pioneering medical device company, today announced significant advancements in its ContiReflex® artificial urinary sphincter and Testi10TM testicular prosthesis lines, showcased in recent high-profile scientific forums.
ContiReflex®: Innovations in Managing Male Incontinence
The new generation ContiReflex® artificial urinary sphincter introduces a dual-bladder system in its pressure regulating balloon (PRB) to effectively manage male stress incontinence, particularly following radical prostatectomy. This technology was recently detailed in a paper presented at the prestigious American Urological Association (AUA) meeting, signaling a major leap forward in patient care.
Key Enhancements and Clinical Data:
- Precision Cuff Sizing: The device's cuffs range from 3.5 to 5 cm, adjustable in 0.25 cm increments, allowing for precise customization to patient anatomy.
- Surgical Technique Improvements: Predominantly using a two-incision method, the device has shown promising early safety outcomes in a study involving 50 patients.
- Strong Safety Profile: Early findings revealed minimal complications, with a notable 98% device survival rate at 18 months, as reported in the study.
Testi10: Setting New Standards in Testicular Prosthetics
Rigicon's Testi10 testicular prosthesis has been recognized for its exceptional reliability and safety in a comprehensive study published in the International Journal of Impotence Research. The study, involving 427 patients, demonstrated a survival rate of 99.8% over 54 months, affirming the prosthesis's superior design and performance.
Device Features and Performance Insights:
- Model Variety: The Testi10 is available in multiple models, including saline-filled and solid silicone, to suit diverse patient needs.
- Impressive Reliability: With a very low revision rate and no significant complications, the device underscores Rigicon's commitment to quality and safety.
A Dedication to Clinical Excellence and Patient Outcomes:
"These significant milestones, achieved through rigorous research and peer-reviewed by the global medical community, underscore our commitment to innovation and excellence in patient care," said Professor Steven K Wilson, Global Medical Director at Rigicon. "Presenting our findings at the AUA meeting and publishing in a respected journal are testaments to the scientific validity and potential impact of our products."
Rigicon remains at the forefront of urological health, driving advancements that redefine treatment standards and improve patient lives worldwide.
Media Contact
Savas Karaoglu, Rigicon Inc, 1 8882029790, [email protected], www.rigicon.com
SOURCE Rigicon Inc
Share this article